Oligoclonal and Polyclonal Antibody Preparations

Gupta, Rishab K.; Glassy, Mark C.

doi:10.1002/9783527682423.ch44

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pritumumab Clinical Trials1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three of 291 the other cases were unchanged (NC), and in 2 cases 292 pritumumab showed no effect. of mAbs [4,9] and pritumumab could be a component.…”

Section: Pritumumab Clinical Trialsmentioning

confidence: 99%

Unconventional immunotherapy with an unconventional target

Glassy¹

2020

HAB

Self Cite

View full text Add to dashboard Cite

Pritumumab, a natural human IgG1 kappa antibody was obtained from a regional draining lymph node of a patient with cervical carcinoma through traditional hybridoma technology. Specificity analysis of the target antigen, an altered form of vimentin called, ecto-domain vimentin (EDV), shows it to be limited to cell surface expression on cancer cells. Clinically, 249 brain cancer patients were treated with a low dose pritumumab regimen, either at 1 mg once a week or 1 mg twice a week, and of those evaluated overall response rates of between 25–30% were seen with several complete and partial responses. A clinical trial assessing higher doses of pritumumab as a therapeutic for brain cancer is expected to begin this year. Overall, these data together suggest pritumumab is suitable for further development as an anti-tumor therapeutic.

show abstract

“…Three of 291 the other cases were unchanged (NC), and in 2 cases 292 pritumumab showed no effect. of mAbs [4,9] and pritumumab could be a component.…”

Section: Pritumumab Clinical Trialsmentioning

confidence: 99%

Unconventional immunotherapy with an unconventional target

Glassy¹

2020

HAB

Self Cite

View full text Add to dashboard Cite

show abstract

Oligoclonal and Polyclonal Antibody Preparations

Cited by 1 publication

References 59 publications

Unconventional immunotherapy with an unconventional target

Unconventional immunotherapy with an unconventional target

Contact Info

Product

Resources

About